While earnings from Trulieve and Ascend Wellness contained some negative surprises, CEOs see richer returns ahead for 2022 amid multi-state rollouts.
Biotech Stock News: NervGen Pharma (TSXV: NGEN) Receives Approval to Proceed to the Final Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q1 2022 Results
Do You Want Straight Forward Views On What's Happening With The Stock Market, Direct to Your Inbox?
Help yourself with our FREE email newsletter designed to help you protect and grow your portfolio. Sign up now:
By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!
Comments